SkinBioTherapeutics PLC Result of AGM (5117X)

TIDMSBTX

RNS Number : 5117X

SkinBioTherapeutics PLC

19 December 2019

SkinBioTherapeutics plc

(the "Company")

Result of AGM

SkinBioTherapeutics plc (AIM: SBTX), announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.

For more information, please contact:

 
 SkinBioTherapeutics plc                     Tel: +44 (0) 161 468 
  Stuart Ashman, CEO                          2760 
  Doug Quinn, CFO 
 Cairn Financial Advisers LLP (Nominated     Tel: +44 (0) 20 7213 
  Adviser)                                    0880 
  Tony Rawlinson / Sandy Jamieson 
 SP Angel Corporate Finance (Joint Broker)   Tel: +44 (0) 20 3470 
  Vadim Alexandre / Abigail Wayne             0470 
 Turner Pope Investments (Joint Broker)      Tel: +44 (0) 20 3657 
  Andy Thacker / Zoe Alexander                0050 
 
   Instinctif Partners                         Tel: +44 (0) 20 7457 
   Melanie Toyne-Sewell / Phil Marriage        2020 
   / Nathan Billis                             SkinBio@instinctif.com

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by Dr. Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGCKCDQDBDDABD

(END) Dow Jones Newswires

December 19, 2019 06:47 ET (11:47 GMT)

Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024